ArticleJournal of preventive medicine and hygiene2025
Hepatitis C Virus Infection in Hemodialysis in Cameroon: Prevalence and Incidence.
Article in Journal of preventive medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemodialysis (HD) is the world's most prevalent kidney replacement therapy for end-stage renal disease patients. Hepatitis C virus infection (HCV) is highly prevalent in patients undergoing HD. There are no reports of the epidemiology of HCV viremia and HCV incidence rate based on prospective studies in HD units in Cameroon. This study evaluated the prevalence and incidence rate of HCV based on anti-HCV antibody (Ab) and HCV-RNA detection. Methods: We conducted a controlled prospective study in three hemodialysis centers in Cameroon, from October 2021 to January 2023. The HEXAGON HCV rapid kit was used to detect anti-HCV Ab, and HCV-RNA was searched using the Xpert® HCV Viral Load technology. We performed a Wilcoxon test and the chi-square or Fisher exact test in statistical analyses. Results: A total of 205 HD patients were enrolled with a mean age of 47.7 ±14.5 years and median hemodialysis duration of 36 months (IQR: 12-72). Anti-HCV Ab was positive in 59 patients, giving a prevalence of 28.8% (95% CI: 22.7-35.5). This Anti-HCV Ab infection was mainly found in patients with a relatively long period of HD (P = 0,00002). Of the 59 anti-HCV Ab-positive patients, HCV-RNA was detected in 42, with the HCV active infection prevalence of 71.2% (95% CI: 57.9-82.2). A high viral load (HCV RNA > 800,000 UL/ml) was detected in 31% (95% CI: 17.6-47.1). A total of 125 patients with a negative status at the start of the study (M0) were prospectively followed up. After seven months (M7), 15 [12%; 95% CI: 06.9-19.)] became HCV positive, with an incidence rate of 20.6 cases per 100 patients-years. Conclusion: There is a high prevalence of HCV infection and HCV incidence rate in this study. Strategies aimed at decreasing HCV infection in HD centers in Cameroon are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.